Term ended Aug 10, 2019 · Medium confidence
20-year base term ended Aug 10, 2019
Why Medium: A parent in the chain could not be resolved.
Held by Novartis AG
Filed Dec 14, 2001 as application 10/022,148 · Granted May 20, 2003
Base term, 20 years from filing
Today
Term ended Aug 10, 2019
1999
2026
Clock starts
Aug 10, 1999
Aug 10, 1999
Term ended
Aug 10, 2019
Aug 10, 2019
Granted
May 20, 2003
May 20, 2003
base term
after the term ends
fee events
Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
None
Term adjustment
No prosecution delay on this record.
None
Terminal disclaimer
No disclaimer on this record.
3 of 3
Maintenance fees paid
Three maintenance fees fall due, at 3.5, 7.5 and 11.5 years from grant. This counts the ones the record shows paid.
52
Family applications on record here
Applications sharing this one's continuity chain whose file history this site holds. The family may have others.
This patent's term is its 20-year base term, with no adjustment for prosecution delay. All three maintenance fees were paid, so no fee lapse ended it. Confidence: Medium. from the record
How we calculated this date
One row per rule, each showing its own input and what it did to the date. A step we could not verify says so instead of resolving itself.
| Step | Input | Date after this step | Confidence |
|---|---|---|---|
| Base term, 20 years from filing | Clock starts Aug 10, 1999, when application 09/371,747, the earliest non-provisional in its chain, was filed (this one was filed Dec 14, 2001); a parent in its chain could not be resolved (the next row) | Aug 10, 2019 | High confidence |
| Continuity chain | A parent in the chain could not be resolved | dated from this application's own claim | Medium confidence |
| Patent term adjustment | None on file | no change | High confidence |
| Terminal disclaimer cap | None on record | no cap applied | High confidence |
| Patent term extension | None on file | no change | High confidence |
| Fee events | 3 of 3 maintenance fees paid | term ended | High confidence |
| Computed term end | The steps above, in order | Aug 10, 2019 | Medium confidence |
This family
| US 6,596,700 | Lapsed on the fee record Jul 2011 | Jul 2011 |
| US 6,566,344 | this patent Aug 2019 | Aug 2019 |
| US 6,569,837 | Term ended no later than Oct 2020 | no later than Oct 2020 |
| US 6,787,526 | Lapsed on the fee record Sep 2012 | Sep 2012 |
| US 6,946,450 | Term ended Aug 2019 | Aug 2019 |
| US 7,608,600 | In force no later than Sep 2028 | no later than Sep 2028 |
| US 7,662,798 | Lapsed on the fee record Feb 2022 | Feb 2022 |
| Application 11/005,440 | Abandoned not computed | not computed |
8 of 52 applications in this family shown, earliest filings first. The applications whose file history this site holds. The family may have others.
Assignments
Assignment documents as recorded at the USPTO, oldest first, with the reel and frame each was recorded at. A recorded assignment is a filed document, not a statement of current ownership, and the absence of a later one is not evidence that the last one still stands.
| Recorded | Assignor | Assignee | Conveyance |
|---|---|---|---|
| Jun 3, 2002 Reel 12937, frame 346 | Centre National de la Recherche Scientifique (CNRS) | L'Universite Montpellier II (Umii) | Assignment of Assignor's Interest |
| Aug 19, 2002 Reel 13193, frame 841 | Novirio Pharmaceuticals Limited | Idenix Pharmaceuticals Inc. | Change of Name |
| Feb 6, 2003 Reel 13718, frame 543 | Novirio Pharmaceuticals Limited | Idenix Pharmaceuticals Inc. | Certicate of Domestication Incorporation in Delaware |
| Mar 26, 2014 Reel 32535, frame 402 | Idenix Pharmaceuticals, Inc. | Novartis AG | Assignment of Assignor's Interest |
Sources
Google Patents · The patent document at USPTO · Assignment records at USPTO
USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup
Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
Citations
61
later US patents cite this one
That is top 25% of utility patents granted in 2003 in our data, the only group it is compared against.
How we rank
Every date shows its work: the base term, any term adjustment or extension, any disclaimer cap, and the maintenance fee record, each with a confidence tier. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.